[1] |
ZHANG Chi, CHEN Jiahui, LIN Jinyi, WANG Yan, ZHANG Sijia, ZHU Wei, CHENG Leilei.
Validation of a scale for evaluating the cardiovascular risk after breast cancer therapy: the clinical scale for breast cancer treatment related cardiovascular toxicity
[J]. China Oncology, 2022, 32(1): 54-60.
|
[2] |
JIN Yizi, LIN Mingxi, ZHANG Jian.
Targeting DNA damage response deficiency in the treatment of breast cancer
[J]. China Oncology, 2022, 32(1): 61-67.
|
[3] |
Expert group of expert consensus on neoadjuvant treatment of breast cancer in China (2021 edition) .
Expert consensus on neoadjuvant treatment of breast cancer in China (2021 edition)
[J]. China Oncology, 2022, 32(1): 80-89.
|
[4] |
Tumor Support and Rehabilitation Therapy Group, the Oncology Committee of Chinese Medical Association.
Clinical practice guidelines for cancer-related fatigue in China (2021 edition)
[J]. China Oncology, 2021, 31(9): 852-872.
|
[5] |
ZHU Yihui, LI Ting, HU Xichun.
Clinical research progress and prospect of trastuzumab deruxtecan
[J]. China Oncology, 2021, 31(8): 754-761.
|
[6] |
GAO Heli, XU Jin, YU Xianjun.
Advances in clinical diagnosis and treatment of gastroenteropancreatic neuroendocrine tumor G3
[J]. China Oncology, 2021, 31(7): 567-573.
|
[7] |
LI Haizhou , ZHANG Yanwei , XU Yingjie , YANG Men , ZHANG Lei , HAN Jingjun .
miR-933 inhibits proliferation, migration and invasion of lung cancer cell lines by regulation of KLF6 gene
[J]. China Oncology, 2021, 31(7): 581-588.
|
[8] |
YANG Jia , LIU Shuyuan , WANG Yingying , LI Yingfu , MA Qianli , LI Yu , WANG Yongrong , LI Chuanyin , TAN Fang .
The association of polymorphisms in TNF-α gene with non-small cell lung cancer in Han population of Yunnan Province
[J]. China Oncology, 2021, 31(7): 616-628.
|
[9] |
YI Weili , ZHAO Wencheng , HUANG Dongning , QIN Li , WU Xintian , ZHOU Fei , WU Fengying .
Analysis of immune-related adverse events and its correlation with efficacy of anti-PD-1 monotherapy in advanced non-small cell lung cancer
[J]. China Oncology, 2021, 31(3): 203-211.
|
[10] |
ZHOU Hongyu , LI Haoran , CHENG Xi , CHEN Lihua , YANG Yufei , CHANG Bin .
Clinical characteristics of 11 patients with small cell carcinoma of the ovary, hypercalcemic type and literature review
[J]. China Oncology, 2021, 31(2): 136-142.
|
[11] |
ZHAO Yuanyuan , ZHOU Jianying , FAN Yun , WANG Jialei , HUANG Dingzhi , LI Junling , SHI Meiqi , LIU Jiwei , YAO Yu , WU Lin , YAO Wenxiu , ZHANG Li .
Advances in the treatment of BRAF V600-mutant non-small cell lung cancer
[J]. China Oncology, 2021, 31(12): 1145-1152.
|
[12] |
LI Zeng , WU Yi , CHEN Zhuzhong , CHEN Li , LIAO Hong , MAO Dun , XIAO Yingming , XIE Hongping , LI Xiuli , YANG Shengke , ZHOU Shukui , ZHONG Lei , LU Hao , CHEN Yongji .
The value of 18 F-PSMA-1007 PET/CT in the early diagnosis and clinical treatment of patients with biochemical recurrence after radical prostatectomy
[J]. China Oncology, 2021, 31(11): 1081-1087.
|
[13] |
SHEN Yujia , FU Xiaolong .
Research progress of immune contexture in tumorigenesis, progression and prognostic relevance of non-small cell lung cancer
[J]. China Oncology, 2021, 31(11): 1115-1125.
|
[14] |
BAO Lingjie , NING Yan , YI Xiaofang .
Synchronous primary fallopian tube and endometrial cancers: a report of three cases and literature review
[J]. China Oncology, 2021, 31(10): 949-953.
|
[15] |
HE Xi, JIAO Xiaodong, ZANG Yuansheng.
Clinical research progress of tumor mutational burden in EGFR-mutant advanced non-small cell lung cancer
[J]. China Oncology, 2021, 31(1): 69-75.
|